title: Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab - a case report.
abstract: Much excitement has been generated with the approval of idarucizumab, a humanized monoclonal antigen-binding antibody fragment that is capable of reversing the anticoagulant activity of dabigatran. Here, we describe our initial experience of using tissue plasminogen activator (tPA) in an acute posterior circulation ischemic stroke after dabigatran reversal with idarucizumab. Both treatments were well tolerated and no hemorrhagic or procoagulatory complications were observed. We propose that the option of dabigatran reversal needs to be considered for contemporary treatment concepts of acute ischemic stroke.
authors.affiliation: Department of Neurology Christian Doppler Medical Center Paracelsus Medical University Salzburg Austria.
authors.forename: Johannes Sebastian
authors.initials: JS
authors.lastname: Mutzenbach
authors.affiliation: Department of Neurology Christian Doppler Medical Center Paracelsus Medical University Salzburg Austria.
authors.forename: Slaven
authors.initials: S
authors.lastname: Pikija
authors.affiliation: Department of Neurology Christian Doppler Medical Center Paracelsus Medical University Salzburg Austria.
authors.forename: Ferdinand
authors.initials: F
authors.lastname: Otto
authors.affiliation: Department of Neurology Christian Doppler Medical Center Paracelsus Medical University Salzburg Austria.
authors.forename: Ursula
authors.initials: U
authors.lastname: Halwachs
authors.affiliation: Division of Neuroradiology Christian Doppler Medical Center Paracelsus Medical University Salzburg Austria.
authors.forename: Friedrich
authors.initials: F
authors.lastname: Weymayr
authors.affiliation: Department of Neurology Christian Doppler Medical Center Paracelsus Medical University Salzburg Austria; Department of Neurology Klinikum rechts der Isar Technische Universität München München Germany.
authors.forename: Johann
authors.initials: J
authors.lastname: Sellner